ABL Bio Signs Technology Export Deal Worth 1.3 Trillion KRW with Sanofi
[Asia Economy Reporter Lee Seon-ae] ABL Bio announced on the 12th that it has signed a technology transfer and co-development agreement worth KRW 1.272 trillion for ‘ABL301’ with Sanofi.
This agreement mainly involves the transfer of exclusive rights to develop and commercialize ABL301 in global markets.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
ABL301 is a bispecific antibody drug candidate that combines an antibody targeting aggregated alpha-synuclein with the BBB shuttle platform (Grabody-B), an IGF1R target that maximizes penetration of the Blood Brain Barrier (BBB).
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
